http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111718380-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F15-00 |
| filingDate | 2020-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111718380-B |
| titleOfInvention | Carboline ruthenium complex and preparation method and application thereof |
| abstract | The invention provides a carboline ruthenium complex and a preparation method and application thereof, belonging to the technical field of biological medicines. The series of carboline ruthenium complexes provided by the invention can inhibit tumor metastasis, have an inhibition effect on primary tumors, and have high biological activity. The complex provided by the invention has a selective killing effect on tumor cells, can form relatively stable spherical nano molecules in vitro, and can interact with DNA and transferrin; in vivo experiments, the S180 mouse sarcoma model evaluated the inhibitory effect of the complex on primary tumors, the LLC anti-metastasis model evaluated the anti-metastasis effect of the complex on lung cancer, and the distribution of the complex in vivo was determined by ICP-MS, while immunohistochemistry and immunofluorescence analysis were performed on tumor tissues, showing that complex 2b can inhibit the growth of primary tumors in vivo and the metastasis of tumors on lungs. |
| priorityDate | 2020-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 87.